CAR-T therapy for T-cell lymphoma/leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is studying whether a new kind of cellular therapy, called anti-CD7 CAR-T, can help people with relapsed or refractory T-cell lymphoma/leukemia by targeting a specific protein (CD7) on their cancer cells. The treatment uses your own immune cells that are reprogrammed to find and destroy the malignant cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have T-cell leukemia/lymphoma that has relapsed (returned) or is refractory (not responding to treatment), and you have tried several treatments before.
- A test must show that your cancer cells have the CD7 protein (they are 'CD7-positive').
- You are not within 6 months of a donor stem cell transplant.
- You have not been treated with CAR-T or other gene-modified cell therapies before.
- Your general health is reasonably good (ECOG score 0-2) and doctors expect you to live more than 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a new treatment that uses your own immune cells, modified to attack cancer cells, followed by a stem cell transplant to help rebuild your immune system. It is for people with a type of T-cell lymphoma that has not responded to standard treatments.
This trial tests a new type of immunotherapy called anti-CD7 CAR-T cells for children and young adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to see if these specially engineered immune cells can find and destroy cancer cells that carry the CD7 protein.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
Hear when a new T Lymphoblastic Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.